New signaling mechanism implicated in the development of ventricular fibrillation

NewsGuard 100/100 Score

A study led by Guadalupe Sabio and José Jalife at the Centro Nacional de Investigaciones Cardiovasculares (CNIC) in Madrid has identified a new signaling mechanism implicated in the development of ventricular fibrillation, a type of arrhythmia, or irregular heartbeat. The study findings, published in the journal Nature Cardiovascular Research, offer promise of future treatment options for this life threatening condition.

Ventricular fibrillation is the most frequent cause of sudden cardiac death. Although aging is an established risk factor for the development of cardiac arrhythmia, the mechansims underlying this connection have been hard to pin down, hindering progress toward the development of specific treatments.

The heartbeat is a cycle of regular contractions of the cardiac muscle that pump blood efficiently throughout the body. Achieving this requires the highly coordinated contraction of the cardiac muscle cells in a meticulously orchestrated pattern. With the development of an arrhythmia, the cardiac cycle speeds up and becomes irregular, with potentially life threatening consequences.

Working with animal models, the CNIC team discovered a connection between the development of ventricular fibrillation and the activation of two key signaling proteins, the stress kinases p38γ and p38δ. The link with these enzymes was independent of the sex of the animals.

This discovery opens the way to new possible intervention strategies for this condition.

When the scientists examined the hearts of old mice, they found that the activation of p38γ and p38δ was increased. A similar increase in the activity of these enzymes was also observed in the hearts mice with a genetic or pharmacologically induced predisposition to developing ventricular arrhythmias. Together, these results suggest that stress signaling via p38γ and p38δ likely plays an important role in the development of this condition.

When we found that activation of these p38 kinases was a shared feature of distinct arrhythmogenic situations, we realized that they likely play an important role that we needed o investigate."

Según Rafael Romero, first author

An in-depth analysis of this signaling pathway revealed that when these protein kinases are activated they alter the electrical properties of cardiomyocytes (the heart's muscle cells), triggering the appearance of arrhythmias. This onset of arrhythmia involves p38-mediated alterations to specific ion channels that coordinate cardiomyocyte contraction.

The scientists found that p38γ and p38δ phosphorylate a receptor called ryanodine receptor 2 and another protein called SAP97, resulting in a mislocalization of the potassium ion channel Kv4.3. These molecular changes lead to premature ventricular activation and an increased susceptibility to ventricular fibrillation.

The study findings identify a promising therapeutic target for the development of new strategies to prevent sustained ventricular fibrillation and provide protection against this serious condition.

The CNIC, directed by Dr. Valentín Fuster, is dedicated to cardiovascular research and the translation of knowledge gained into real benefits for patients. The CNIC has been recognized by the Spanish government as a Severo Ochoa center of excellence (award number CEX2020-001041-S, funded by MICIN/AEI/10.13039/501100011033). The center is financed through a pioneering public-private partnership between the government (through the Carlos III Institute of Health) and the Pro-CNIC Foundation, which brings together 12 of the most important Spanish private companies.

Source:
Journal reference:

Romero-Becerra, R., et al. (2023). p38γ/δ activation alters cardiac electrical activity and predisposes to ventricular arrhythmia. Nature Cardiovascular Research. doi.org/10.1038/s44161-023-00368-x.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Expanding research and clinical options for children with cancer